1,258 Shares in Cencora, Inc. $COR Purchased by Great Waters Wealth Management

Key Points

• Great Waters Wealth Management invested approximately $377,000 in Cencora, Inc., acquiring 1,258 shares during the second quarter.
• Cencora reported a net margin of 0.60% and a quarterly revenue of $80.66 billion, beating analysts' expectations and showing an 8.7% increase from the previous year.
• The company recently announced a quarterly dividend of $0.55, representing a 0.8% dividend yield with a payout ratio of 22.63%.

Great Waters Wealth Management acquired a new stake in Cencora, Inc. (NYSE:COR - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,258 shares of the company's stock, valued at approximately $377,000.

Several other hedge funds also recently modified their holdings of the business. Price T Rowe Associates Inc. MD raised its stake in Cencora by 8.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 9,647,310 shares of the company's stock worth $2,682,821,000 after acquiring an additional 787,858 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of Cencora by 7.2% in the first quarter. Wellington Management Group LLP now owns 5,421,262 shares of the company's stock valued at $1,507,599,000 after buying an additional 363,402 shares during the last quarter. Boston Partners raised its holdings in shares of Cencora by 8.1% in the first quarter. Boston Partners now owns 5,411,193 shares of the company's stock valued at $1,505,984,000 after buying an additional 404,093 shares during the last quarter. Invesco Ltd. raised its holdings in Cencora by 42.1% during the 1st quarter. Invesco Ltd. now owns 4,607,964 shares of the company's stock worth $1,281,429,000 after purchasing an additional 1,364,433 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its holdings in Cencora by 9.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,711,281 shares of the company's stock worth $475,890,000 after purchasing an additional 154,311 shares during the last quarter. 97.52% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Jefferies Financial Group boosted their target price on Cencora from $275.00 to $300.00 and gave the stock a "hold" rating in a research report on Monday, June 30th. Morgan Stanley set a $330.00 target price on Cencora and gave the stock an "equal weight" rating in a report on Wednesday, July 16th. Finally, Wells Fargo & Company upped their price objective on Cencora from $337.00 to $354.00 and gave the company an "overweight" rating in a report on Wednesday, August 13th. Nine investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $311.25.

Insider Transactions at Cencora

In other news, CEO Robert P. Mauch sold 5,097 shares of the business's stock in a transaction dated Thursday, September 18th. The stock was sold at an average price of $290.00, for a total value of $1,478,130.00. Following the completion of the sale, the chief executive officer owned 39,274 shares of the company's stock, valued at approximately $11,389,460. The trade was a 11.49% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Chairman Steven H. Collis sold 31,350 shares of the company's stock in a transaction that occurred on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total value of $9,087,111.00. Following the transaction, the chairman directly owned 305,913 shares of the company's stock, valued at $88,671,942.18. The trade was a 9.30% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 70,572 shares of company stock valued at $20,559,030. 10.80% of the stock is currently owned by corporate insiders.

Cencora Stock Down 0.4%

Cencora stock traded down $1.04 during mid-day trading on Monday, reaching $288.98. The stock had a trading volume of 1,097,300 shares, compared to its average volume of 1,583,695. Cencora, Inc. has a fifty-two week low of $218.65 and a fifty-two week high of $309.35. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.53 and a current ratio of 0.90. The stock's 50-day simple moving average is $292.42 and its 200-day simple moving average is $287.29. The firm has a market capitalization of $56.03 billion, a PE ratio of 29.73, a price-to-earnings-growth ratio of 1.48 and a beta of 0.62.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $4.00 EPS for the quarter, topping analysts' consensus estimates of $3.79 by $0.21. The business had revenue of $80.66 billion for the quarter, compared to analyst estimates of $80.34 billion. Cencora had a return on equity of 267.36% and a net margin of 0.60%.Cencora's quarterly revenue was up 8.7% compared to the same quarter last year. During the same period last year, the company posted $3.34 earnings per share. On average, sell-side analysts forecast that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Friday, August 15th were paid a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, August 15th. This represents a $2.20 annualized dividend and a yield of 0.8%. Cencora's payout ratio is 22.63%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.